Boehringer Ingelheim acquires Northern Biologics

By The Science Advisory Board staff writers

May 14, 2020 -- Boehringer Ingelheim on May 14 announced the acquisition of Northern Biologics, including its preclinical cancer antibody pipeline.

Boehringer Ingelheim will be responsible for clinical, regulatory, and commercial development of the acquired programs. The acquisition transfers assets targeting tumor stromal and myeloid cells.

The first program, developing an antibody inhibitor of periostin, targets cold tumors and is in late preclinical development. The second program, for development of a myeloid cell regulator, enhances antitumor T-cell function and complements Boehringer Ingelheim's existing portfolio.

Northern Biologics will retain its name and continue to drive preclinical research for MSC-1, an anti-LIF 1 antibody candidate. Northern Biologics was established in Toronto in 2014 by founding investor Versant Ventures.

Boehringer Ingelheim expands COVID-19 collaborations
Boehringer Ingelheim announced that it is significantly increasing support for the fight against COVID-19, particularly by adding a number of strategic...
AACR launches $36M genomics project with big pharma
The American Association for Cancer Research (AACR) is launching a $36 million research project in collaboration with big pharma to expand its Genomics...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter